Form 4: Zivo Bioscience Director Boosts Stake

Zivo Bioscience Director and 10% owner Laith L. Yaldoo acquired 1,543 shares of common stock, increasing his indirect beneficial ownership.

Summary

• Laith L. Yaldoo, a Director and 10% Owner of Zivo Bioscience, Inc. (ZIVO), reported a transaction.
• On February 27, 2026, Yaldoo acquired 1,543 shares of Zivo Bioscience Common Stock.
• The shares were purchased at a price of $9.72 per share.
• Following this transaction, Yaldoo beneficially owns a total of 583,615 shares.
• The ownership of these shares is indirect, held through HEP Investment, LLC.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. Insider buying indicates confidence from a key stakeholder, which can reassure investors, though a single transaction does not guarantee future performance.

Positives

• A Director and 10% Owner, Laith L. Yaldoo, purchased additional shares of Zivo Bioscience common stock, signaling confidence in the company's future prospects.
• The acquisition of 1,543 shares at $9.72 each increases the insider's total beneficial ownership to 583,615 shares.

Industry Context

StockSavvy.ai notes that insider buying, particularly from a director and significant owner, is often interpreted by the market as a positive signal, suggesting that those with the most intimate knowledge of the company believe its stock is undervalued or has strong future potential. This transaction occurs within the broader biotech and bioscience industry, where investor sentiment can be heavily influenced by company-specific developments and insider confidence.

Stakeholder Impact

• Shareholders may view the insider purchase as a positive indicator of management's confidence in the company's future, potentially bolstering investor sentiment.

Key Dates

Recommendation

A seasoned investor would likely view this insider purchase as a positive signal, suggesting that a director and significant owner sees value in the company at the current price. While not a 'strong buy' on its own, it provides a favorable data point that could support a 'hold' recommendation, encouraging investors to maintain their positions or consider initiating a small one, pending further fundamental analysis and market developments.

Keywords

Zivo Bioscience, ZIVO, Insider Trading, Director Purchase, Stock Acquisition, Beneficial Ownership, Form 4